The Synthetic Nucleic Acid Platforms for HIV-1 (SNAPH): (R61/R33 Clinical Trial Not Allowed) funding program from the National Institutes of Health (NIH) seeks to advance synthetic nucleic acid platforms for the rapid development and iterative testing of active and passive immunization strategies for HIV prevention, treatment, and cure. This funding opportunity will use a milestone-driven, biphasic award mechanism. Transition to the second phase will depend on the successful completion of milestones. Applications are open to researchers in the USA and worldwide. Applicants may apply for up to 750,000 USD/year for up to 5 years. Opportunity ID: RFA-AI-23-026. Letters of intent are due July 2, 2023. Full applications are due August 2, 2023.